Next Article in Journal / Special Issue
Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
Previous Article in Journal
An Exonuclease III Protection-Based Electrochemical Method for Estrogen Receptor Assay
Previous Article in Special Issue
Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer
Open AccessReview

Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection

Laboratory of Cancer Biology, Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Hangzhou 310029, China
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(5), 10307-10331;
Received: 11 March 2013 / Revised: 1 April 2013 / Accepted: 25 April 2013 / Published: 16 May 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
Epigenetic alterations including DNA methylation and microRNAs (miRNAs) play important roles in the initiation and progression of human cancers. As the extensively studied epigenetic changes in tumors, DNA methylation and miRNAs are the most potential epigenetic biomarkers for cancer diagnosis. After the identification of circulating cell-free nuclear acids, increasing evidence demonstrated great potential of cell-free epigenetic biomarkers in the blood or other body fluids for cancer detection. View Full-Text
Keywords: cancer; biomarker; DNA methylation; miRNAs cancer; biomarker; DNA methylation; miRNAs
MDPI and ACS Style

Ma, Y.; Wang, X.; Jin, H. Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. Int. J. Mol. Sci. 2013, 14, 10307-10331.

Show more citation formats Show less citations formats

Article Access Map

Only visits after 24 November 2015 are recorded.
Back to TopTop